These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 4948221)

  • 21. Bacterial negativity and reactivation (relapse) of lepromatous outpatients under sulfone treatment.
    Quagliato R; Bechelli LM; Marques RM
    Int J Lepr Other Mycobact Dis; 1970; 38(3):250-63. PubMed ID: 4993550
    [No Abstract]   [Full Text] [Related]  

  • 22. Growing points in leprosy research. 2. Epidemiology.
    Meade TW
    Lepr Rev; 1974 Mar; 45(1):15-21. PubMed ID: 4602616
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary dapsone-resistant leprosy in San Francisco.
    Gelber RH
    Int J Lepr Other Mycobact Dis; 1984 Dec; 52(4):471-4. PubMed ID: 6399067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. POLYSENSITIVITY TO ANTI-LEPROSY DRUGS.
    BROWNE SG
    Lepr Rev; 1964 Jul; 35():165-7. PubMed ID: 14177691
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of leprosy with clofazimine, rifampicin and Bayrena.
    Languillon J
    Lepr Rev; 1975 Jun; 46(2 Suppl):81-4. PubMed ID: 1100968
    [No Abstract]   [Full Text] [Related]  

  • 27. Sulfone resistance and leprosy control.
    Lechat MF
    Int J Lepr Other Mycobact Dis; 1978; 46(1):65-7. PubMed ID: 565757
    [No Abstract]   [Full Text] [Related]  

  • 28. [On the chemoresistance of the Hansen bacillus and the treatment of leprosy with drug associations].
    Floch HA
    Bull Soc Pathol Exot Filiales; 1966; 59(2):188-92. PubMed ID: 6012833
    [No Abstract]   [Full Text] [Related]  

  • 29. [Immunologic and histomorphologic features of responsiveness in patients with leprosy at different stages of treatment].
    Strukov AI; Babaiants RS; Shakhtmeĭster IIa; Kopieva TN; Goloschapov NM
    Vestn Dermatol Venerol; 1972 Oct; 46(10):8-12. PubMed ID: 4569353
    [No Abstract]   [Full Text] [Related]  

  • 30. [Chemotherapy of leprosy--effect of the anti-leprotic agent on the growth of acid-fast bacilli in cutaneous and mucous tissue].
    Hirano E
    Iryo; 1972 Mar; 26(3):243-53. PubMed ID: 4554827
    [No Abstract]   [Full Text] [Related]  

  • 31. A new method for the manufacture of bis(4-aminophenyl)-sulfone and the anti-leprosy, anti-tuberculosis, and antibiotic activities of some new derivatives related to the drug. I.
    Sah PP; Peoples SA; Kwan ST; Sah HJ
    Arzneimittelforschung; 1967 Apr; 17(4):425-51. PubMed ID: 5632435
    [No Abstract]   [Full Text] [Related]  

  • 32. Follow-up study of nerve lesions in leprosy using the time intensity curve test.
    Magora A
    Int J Lepr Other Mycobact Dis; 1969; 37(2):164-72. PubMed ID: 4310800
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of leprosy by sulfones and delayed action sulfonamides. Comparison of therapeutic results in 100 cases].
    Faye I; Privat Y; Bellossi A
    Bull Soc Med Afr Noire Lang Fr; 1968; 13(1):119-24. PubMed ID: 5713742
    [No Abstract]   [Full Text] [Related]  

  • 34. The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea.
    Lee SB; Kim SK; Kang TJ; Chae GT; Chun JH; Shin HK; Kim JP; Ko YH; Kim NH
    Ann Trop Med Parasitol; 2001 Jun; 95(4):429-32. PubMed ID: 11454253
    [No Abstract]   [Full Text] [Related]  

  • 35. The condition of the peripheral nerve in leprosy under various forms of treatment. Conduction velocity studies in long-term follow-up.
    Magora A; Sheskin J; Sagher F; Gonen B
    Int J Lepr Other Mycobact Dis; 1970; 38(2):149-63. PubMed ID: 5529246
    [No Abstract]   [Full Text] [Related]  

  • 36. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980].
    Guelpa-Lauras CC; Constant-Desportes M; Millan J; Grosset J
    Acta Leprol; 1982; (86-87):77-80. PubMed ID: 6816000
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessment of the bacteriological effect of combined treatment with rifadin, sulfamethoxypyrazine, and isoniazide in lepromatous leprosy.
    Leiber DL; Verhagen AR
    Z Tropenmed Parasitol; 1973 Dec; 24():32-5. PubMed ID: 4592434
    [No Abstract]   [Full Text] [Related]  

  • 38. Mycobacterium leprae in skin and nasal scrapings during sulfone treatment; a review of 146 cases.
    BYERS JL; WOLCOTT RR
    Int J Lepr; 1954; 22(3):285-7. PubMed ID: 13232776
    [No Abstract]   [Full Text] [Related]  

  • 39. [Control of leprosy: fantasies and possibilities].
    Browne SG
    Bull Mem Acad R Med Belg; 1980; 135(3):208-18. PubMed ID: 7004552
    [No Abstract]   [Full Text] [Related]  

  • 40. Studies on sulphone resistant strains of M. leprae in field and institutionalized cases of leprosy.
    Balakrishnan S; Seshadri PS; Neelan PN; Venkataramaniah HN; Harikrishnan S; Bhatia VN
    Lepr India; 1983 Jan; 55(1):71-5. PubMed ID: 6348413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.